Cwm LLC Acquires 19,571 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Cwm LLC grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 471.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 23,722 shares of the company’s stock after buying an additional 19,571 shares during the quarter. Cwm LLC’s holdings in Apellis Pharmaceuticals were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new stake in Apellis Pharmaceuticals during the 1st quarter worth approximately $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Apellis Pharmaceuticals during the 1st quarter worth approximately $89,000. nVerses Capital LLC increased its holdings in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after acquiring an additional 2,100 shares during the period. Russell Investments Group Ltd. increased its holdings in Apellis Pharmaceuticals by 1,300.8% during the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after acquiring an additional 3,330 shares during the period. Finally, Tidal Investments LLC bought a new stake in Apellis Pharmaceuticals during the 1st quarter worth approximately $266,000. Institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Scotiabank assumed coverage on shares of Apellis Pharmaceuticals in a report on Wednesday. They set a “sector outperform” rating and a $35.00 target price on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Wedbush boosted their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Robert W. Baird cut their price target on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, September 23rd. Finally, Wells Fargo & Company cut their price target on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $68.00.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $28.00 on Friday. Apellis Pharmaceuticals, Inc. has a 52-week low of $26.28 and a 52-week high of $73.80. The stock has a market capitalization of $3.40 billion, a price-to-earnings ratio of -8.09 and a beta of 0.87. The company has a fifty day moving average of $34.16 and a 200-day moving average of $39.62. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm’s revenue for the quarter was up 110.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.02) EPS. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.37 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares of the company’s stock, valued at $3,623,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 6.80% of the stock is currently owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).